Cardioprotective effect of *Volvariella volvacea* in streptozotocin administered rat
Introduction

Diabetes mellitus is a potent independent risk factors for cardiovascular disease mediated by increased production of free radicals (Baynes and Thorpe, 1999) and impaired anti-oxidants (Halliwell and Gutteridge, 1990). Free radicals caused oxidative stress damages cellular proteins, membrane lipids and nucleic acids (Maritim et al., 2003) which eventually accelerate micro and macrovascular impediments. Inhibition of intracellular free radical generation to prevent hyperglycemic oxidative stress and related complications in diabetic heart will be an effective therapy.

Since antidiabetic agents in use are ill reputed with side effects, nutraceuticals and functional foods are becoming popular to prevent the diabetes and its hyperglycemic complications (Yang et al., 2008). Natural antidiabetic drugs with anti-oxidant properties would be a promising alternative therapy. Mushrooms besides their rich nutritional values have been considered as remarkable therapeutic agent for diabetes and cardiovascular diseases (Wasser and Weis, 1999). Mushrooms are hypoglycemic (Hwang et al., 2005) and are also rich source of anti-oxidants (Ferreira et al., 2009).

The present study evaluates the anti-oxidant mediated cardioprotective effect of an edible mushroom, Volvariella volvacea in streptozotocin-induced diabetic rats. V. volvacea (paddy straw mushroom or Chinese mushroom) is an edible tropical mushroom and has nutritional, therapeutic (Roy et al., 2014) and anti-oxidant potential (Punitha and Rajasekaran, 2014).

Abstract

The present study examined the cardioprotective role of methanol extract of the edible mushroom Volvariella volvacea against oxidative stress in hyperglycemic rats. Rats divided into 6 groups were administered with nicotinamide and streptozotocin intraperitoneally, except Group I (control). Group II served as diabetic control. Group III was given glibenclamide. Two groups (IV and V) of rats received (200 and 400 mg/kg) mushroom extracts orally for 30 days and Group VI received vitamin E (40 mg/kg). After the treatment period, lipid peroxides, carbonyl end products, advanced glycation end products, reduced glutathione, glutathione peroxidase, glutathione-S transferase, catalase, superoxide dismutase and non-enzymatic anti-oxidants (vitamin C and E) were assessed in the heart tissues of experimental animals. Glycosylated hemoglobin was estimated in blood. Electrocardiography recordings of the treated groups were also done. The results showed that mushroom extract treatment reduced the lipid peroxides, advanced glycation end products and protein carbonyls significantly and reversed the altered anti-oxidant enzymes, and the vitamins.
Materials and Methods

Reagents

Streptozotocin was purchased from the Sigma Chemical Co., USA. All other reagents used were of analytical grade procured from the Himedia Lab, India.

Mushroom extract

V. volvacea was procured from the Directorate of Mushroom Research, Solan, India as dried sample. It was further dried at 50°C for 12 hours and pulverized. The powdered mushroom was extracted with methanol in soxhlet apparatus for 12 hours. The extract was concentrated using rotary vacuum evaporator and stored.

Animals

Male Wistar albino rats (150-175 g) were obtained from the Central Animal Facility, SASTRA University, Thanjavur. They were maintained in the animal room under controlled conditions.

Induction of diabetes

Diabetes was induced in overnight fasted rats by intraperitoneal injection of streptozotocin dissolved in 0.1M cold sodium citrate buffer of pH 4.5 at a dose of 60 mg/kg body weight. Nicotinamide was given (110 mg/kg ip.) 15 min prior to streptozotocin injection. To overcome the drug-induced hypoglycemic state, rats were allowed to drink 5% glucose solution overnight. Hyperglycemia was confirmed 72 hours after streptozotocin administration by measuring tail vein blood glucose with glucometer (One Touch, Switzerland). The rats with blood glucose levels beyond 250 mg/dL were considered diabetic and were used for experimentation.

Experimental protocol

For the treatment, rats were divided into six groups of 6 rats each. Group I was considered as normal control. Group II was diabetic control. Group III received glibenclamide, a standard drug (10 mg/kg p.o.) and was considered as positive control. Group IV and V animals were administered with methanol extract of V. volvacea at two different concentrations, 200 and 400 mg/kg body weight, and Group VI received vitamin E (40 mg/kg body weight) by intragastric intubation. All the doses were administered for 30 days.

Biochemical estimations

At the end of the experimental period, the rats were anesthetized by CO₂ asphyxiation. Blood samples were

Box 1: Quantitative determination of glycosylated hemoglobin by ion exchange resin method

**Principle**

Glycosylated hemoglobin is formed continuously by the addition of glucose by covalent bonding to the amino terminal valine of the hemoglobin beta chain progressively and irreversibly over a period of time and is stable.

A hemolysed preparation of whole blood is mixed continuously for five minutes with a weakly binding cation-exchange resin. The labile fraction is eliminated during the hemolysate preparation and binding. During mixing non-glycosylated hemoglobin binds to the ion exchange resin leaving the glycosylated hemoglobin free in the supernatant which is separated using a resin separator. Absorbance of the supernatant at 415 nm is read. The percent glycosylated hemoglobin is determined by measuring the ratio of absorbance of glycosylated hemoglobin and total hemoglobin fraction of control and test.

**Requirements**

Ion exchange resin (predispensed tubes 3 mL), lysing reagent, resin separator and control (10% glycosylated hemoglobin), heparinized vial, and GlycoHb kit (Kamineni Life Sciences Pvt. Ltd., India).

**Procedure**

Hemolysate preparation

**Step 1**: Dispense 0.5 mL of lysing reagent into tubes labeled as control and test

**Step 2**: Add 0.1 mL of reconstituted and well mixed blood sample into the respective tubes

**Step 3**: Mix well for complete lysis

**Step 4**: Allow to stand for five min

Glycosylated hemoglobin separation

**Step 1**: Remove the cap of ion-exchange resin solution and label control and test

**Step 2**: Add 0.1 mL of hemolysate to the resin tubes

**Step 3**: Insert a resin separator into each tube in such a way that the rubber sleeve is 3 cm above the solution

**Step 4**: Mix the solution using a vortex and keep for five min

**Step 5**: Push the resin separator into the tubes until the resin is firmly packed

**Step 6**: Pour the supernatant directly into a cuvette and measure the absorbance

Total hemoglobin fraction

**Step 1**: Dispense 5.0 mL of distilled water in two test tubes (control and test)

**Step 2**: Add 0.02 mL of hemolysate and read the absorbance after mixing well

**Calculation**

\[ \% \text{Glycosylated Hb} = \frac{\text{Ratio of test}}{\text{Ratio of control}} \times 10 \]

(value of control)

**Video clips**

Hemolysate preparation: 2 min 50 sec

Mixing, glycosylated hemoglobin separation and reading absorbance: 3 min 10 sec
collected by retro-orbital sinus puncture in heparinized vials. Hearts were excised immediately and washed with physiological saline. The heart tissue homogenate prepared using 0.1M Tris HCl buffer (pH 4.7) was used for biochemical estimations. Determination of lipid peroxides (Ohkawa et al., 1979), protein carbonyls (Levine et al., 1994), reduced glutathione (Ellman, 1959), glutathione peroxidase (Rotruck et al., 1973) glutathione-S-transferase (Habig et al., 1974), catalase (Aebi, 1984), superoxide dismutase (Kakkar et al., 1984), vitamin C (Omaye et al., 1979) and vitamin E (Baker et al., 1980) were done in the heart tissue homogenate of all groups of rats. Advanced glycation end products in heart tissues were determined (Nakayama et al., 1993) using multi-mode microplate reader (Biotek, USA). Blood samples collected in heparinized vials were used for glycosylated hemoglobin (HbA1c) estimation using GlycoHb kit, Lifechem™ purchased from Kamineni Life Sciences Pvt. Ltd., India.

**Electrocardiogram**

ECG was recorded using 12 channel polygraph device (Biopack, MPI00, USA). All the rats were anesthetized using ketamine (100 mg/kg i.p) before taking ECG readings. QT, QRS and ST waves were measured for all the groups.

**Statistical analysis**

The results are expressed as Mean ± Standard error of mean. Statistical analysis of the results was done by one way analysis of variance (ANOVA) using GraphPad Prism 5 software, followed by Dunnet’s test. The difference was considered statically significant when p<0.05.

**Results**

Induction of diabetes with streptozotocin led to marked hyperglycemia within 3 days of injection. This hyperglycemic state was accompanied by significantly altered oxidative stress markers and anti-oxidant status. Streptozotocin-treated rats showed elevated levels of lipid peroxides (31.3 ± 0.8 nmol melondialdehyde/mg protein) compared to control (15.3 ± 0.5 nmol melondialdehyde/mg protein).

**Advanced glycation end products** in heart tissues were determined using multi-mode microplate reader (Biotek, USA). Blood samples collected in heparinized vials were used for glycosylated hemoglobin (HbA1c) estimation using GlycoHb kit, Lifechem™ purchased from Kamineni Life Sciences Pvt. Ltd., India.

**Table I**

| Experimental groups | Control | Streptozocotin |
|---------------------|---------|----------------|
|                     |         | Glibenclamide | V. volvacea (200 mg) | V. volvacea (400 mg) | Vitamin E |
| Lipid peroxide (nmol melondialdehyde/mg protein) | 15.3 ± 0.5 | 31.3 ± 0.8a | 18.5 ± 0.7 | 24.1 ± 0.7a | 19.5 ± 0.5 | 20.8 ± 0.8a |
| Protein carbonyl (nmol of carbonyl/mg protein) | 1.9 ± 0.0 | 3.1 ± 0.2a | 2.0 ± 0.1 | 1.9 ± 0.1 | 2.1 ± 0.2 | 1.9 ± 0.1 |
| Advanced glycation end products (AU/mg protein) | 12.3 ± 0.1 | 24.5 ± 0.3a | 15.7 ± 0.2 | 16.5 ± 0.3 | 14.5 ± 0.2 | 19.6 ± 0.2a |
| HbA1c (%) | 7.6 ± 0.2 | 12.2 ± 0.2a | 12.2 ± 0.2a | 8.1 ± 0.2 | 8.1 ± 0.1 | 9.7 ± 0.1a |

Values are expressed as Mean ± SE (n = 6); a indicates significantly different from control p<0.05.

**Table II**

| Experimental groups | Control | Streptozocotin |
|---------------------|---------|----------------|
|                     |         | Glibenclamide | V. volvacea (200 mg) | V. volvacea (400 mg) | Vitamin E |
| GPx (µg of gsh oxidised/min) | 11.4 ± 0.5 | 5.7 ± 0.2a | 9.6 ± 0.3 | 9.0 ± 0.2 | 9.1 ± 0.4 | 9.2 ± 0.5 |
| GST (µg of CDMB conjugation formed/min) | 7.5 ± 0.2 | 4.6 ± 0.3a | 7.2 ± 0.2 | 6.3 ± 0.3 | 6.4 ± 0.2 | 7.0 ± 0.2 |
| CAT (nmol of H2O2 oxidized / min/mg proteins) | 59.0 ± 1.1 | 25.1 ± 0.6a | 49.4 ± 0.6 | 47.8 ± 1.2 | 47.7 ± 1.3 | 49.9 ± 1.1 |
| SOD (IU/mg protein) | 12.8 ± 0.4 | 5.3 ± 0.2a | 9.8 ± 0.3 | 7.7 ± 0.4a | 8.4 ± 0.3 | 8.0 ± 0.3 |
| Vitamin C (µg/mg protein) | 194 ± 1.6 | 111.9 ± 0.8a | 187.6 ± 2.4 | 169.8 ± 1.7 | 181 ± 0.6 | 189.2 ± 1.9 |
| Vitamin E (µg/mg protein) | 5.8 ± 0.1 | 3.0 ± 0.1a | 4.8 ± 0.1 | 4.4 ± 0.3 | 4.2 ± 0.1 | 5.3 ± 0.1 |

Values are expressed as Mean ± SE (N = 6); a indicates significantly different from control p<0.05.
tein) when compared to control group rats (15.3 ± 0.5 nmol melondialdehyde/mg protein) (Table I). Extract (200 mg/kg) showed an increased level to 19.5 ± 0.5 nmol melondialdehyde/mg protein. Glibenclamide and vitamin E-treated groups also exhibited only moderate increase from the control.

Protein carbonyl was also significantly elevated (3.1 ± 0.2 nmol of carbonyl/mg protein) in streptozotocin-treated group. High dose of extract (400 mg/kg) maintained the carbonyl content (2.0 ± 0.02 nmol of carbonyl/mg protein) equal to control group. Treatment with glibenclamide and vitamin E showed only moderate elevation from the control rats.

Advanced glycation end products showed significant elevation in streptozotocin group (24.5 ± 0.3 AU/mg protein) when compared to control group (12.3 ± 0.1 AU/mg protein). However, mushroom extract treatment groups and glibenclamide treatment group exhibited non-significant changes from that of control. Glycosylated hemoglobin (HbA1c) percent was also elevated in streptozotocin-treated hyperglycemic rats (12.2 ± 0.2%). On the other hand, groups administered with extract (8.1 ± 0.1%), glibenclamide (6.9 ± 0.1%) and vitamin E (9.7 ± 0.1%) showed HbA1c content nearer to control level (7.6 ± 0.1%).

Significant reduction of reduced glutathione (GSH) in the streptozotocin-treated group was noted. V. volvacea extract (400 mg/kg) administered rats showed non-significant change from the control level. Rats treated with glibenclamide and vitamin E also exhibited only marginal change from the control values. Anti-oxidant enzyme glutathione peroxidase (GPx) was significantly reduced (5.7 ± 0.2 µg of gsh oxidised/min) in streptozotocin-treated group rats (Table II). Treatment with extract (400 mg/kg) offered protection and the GPx level (9.1 ± 0.4 µg of gsh oxidised/min) was nearer to control (11.4 ± 0.5). Similar trend of results was noted in glibenclamide and vitamin E-treated groups. In streptozotocin-treated groups, hyperglycemia caused significant reduction of glutathione-S-transferase (GST) enzyme (4.6 ± 0.3 µg of CDMB conjugation formed/min). However, mushroom extract received rats showed only moderate reduction (6.4 ± 0.2 µg of CDMB conjugation formed/min) at 400 mg/kg. Rats of groups glibenclamide and vitamin E also exhibited recovery.

![Figure 1: (a) Control group shows normal ECG pattern of QRS, QT and ST waves. (b) STZ treated group rats shows elongated QRS and QT. Prolonged ST interval exhibits with a deep notch of S (arrow). (c, d) Group rats show only moderate alterations of QRS, QT and ST intervals.](image-url)
Enzyme catalase (CAT) activity was significantly reduced (25.1 ± 0.6 nmoles of H₂O₂ oxidized/min/mg proteins) in streptozotocin-treated rats when compared to control group rats (59.0 ± 1.1 nmoles of H₂O₂ oxidized/min/mg proteins). Mushroom extract (400 mg/kg) treatment, however, reversed the level nearer to control. Treatment with glibenclamide and vitamin E also showed marked increase towards control level. Superoxide dismutase (SOD) was significantly reduced by hyperglycemia in streptozotocin-treated groups when compared to control rats (12.8 ± 0.4 IU/mg protein). Moderate increase to control level (8.4 ± 0.3 IU/mg protein) was noted in V. volvacea (400 mg/kg), glibenclamide (9.8 ± 0.3 IU/mg protein) and vitamin E (8.0 ± 0.3 IU/mg protein) administered rats.

Non-enzymatic anti-oxidants vitamin C and E in the hearts of streptozotocin-treated groups were also significantly reduced. Vitamin C and E contents in streptozotocin groups were 111.9 ± 0.8 and 3.0 ± 0.1 µg/mg protein, respectively when compared to control group (194 ± 1.6 and 5.8 ± 0.1 µg/mg protein). VVH treatment (400 mg/kg) showed recovery of vitamin C (181 ± 0.6 µg/mg protein) nearer to control. Glibenclamide and vitamin E-treated groups also exhibited marked increase over to control group rats.

**ECG recording**

The ECG pattern of control group showed normal QRS, QT and ST intervals (Figure 1). However, streptozotocin-treated group exhibited elongated QRS waves. VVH treated rats showed no changes from that of control. Glibenclamide and vitamin E-treated groups also recorded normal pattern. QT interval of streptozotocin-treated rats showed prolonged interval whereas V. volvacea treated rats showed no abnormalities. Similar pattern was observed in glibenclamide and vitamin E groups. Prolonged ST interval with deep notch of S was noted in streptozotocin-treated group. ST segment intervals in other groups V. volvacea, glibenclamide and vitamin E were nearer to control group (Figure 2).

**Discussion**

Diabetic hyperglycaemia caused oxidative stress has been undoubtedly related to cardiac problems. In the present study, oxidative stress markers such as malondialdehyde, protein carbonyls and advanced glycation end products were significantly elevated in streptozotocin-treated groups. These changes were accompanied by reduction in anti-oxidant enzymes and vitamins. Free radicals lead to protein oxidation forming carbonyl groups and are possibly the most immediate vehicle for inflicting oxidative damage on cells (Dalle-Donne et al., 2003). The oxidatively modified protein causes protein fragmentation, crosslinking and unfolding which leads to loss of protein function resulting in cellular impairment (Bulteau et al., 2001). Increased level of malondialdehyde and protein carbonyl in the heart tissues of streptozotocin-treated rats reflect oxidative stress as the consequence of increased free radical generation. Attenuation of lipid peroxidation and protein oxidation was noted in the V. volvacea treated groups, an evidence of prevention of oxidative stress reaction.

Chronic hyperglycaemia usually results in the formation of advanced glycation end products which play a key role in diabetic cardiomyopathy through over production of reactive oxygen species (Norton et al., 1996). In the present study, advanced glycation end level was significantly elevated in the heart of
streptozotocin group showing hyperglycemic oxidative stress. Deposition of advanced glycation end has been reported in atherosclerotic plaques and within myocardium fibers (Sakata et al., 1995) leading to systolic and diastolic dysfunctions and heart failure. Treatment with mushroom extracts at both dose levels didn’t cause significant changes in the advanced glycation end level suggesting that the mushroom is effective in preventing advanced glycation end formation either by exerting hypoglycemic effect or minimizing free radical formation, or by both mechanisms.

Streptozotocin-treated rats had shown a significant increase in the percentage of HbA1c due to persistent hyperglycemia. Increased non enzymatic glycosylation is one of the possible mechanisms linking hyperglycemia and vascular complications of diabetes. During diabetes, the excess glucose present in the blood reacts with hemoglobin to form HbA1C (Kondeti et al., 2010) and is considered as an index for chronic hyperglycemia. Administration of mushroom extracts displayed a remarkable decrease in glycosylated hemoglobin levels which might be due to its normoglycemic activity. The effect is comparable to the hypoglycemic drug glibenclamide.

Reduced glutathione (GSH), a ubiquitous anti-oxidant synthesized in all living cells and functions as an effective intracellular reductant (Rahman and MacNee, 1999), is significantly reduced in streptozotocin-treated groups. Reduced availability of GSH may also reduce the activities of GPx and GST since it acts as an important substrate for GPx, GST and several other enzymes involved in the free radical scavenging action (Rathore et al., 2000). The extract of V. volvacea and glibenclamide treated rats showed increased levels of GSH, suggesting that the extract has the potency to increase biosynthesis of GSH and reduce the oxidative stress.

Streptozotocin-treated groups in the present study showed drastic reduction of GPx and GST indicating severe oxidative stress. GPx maintains the structural and functional integrity of the cytosolic and mitochondrial compartments whereas GST, a group of selenium independent enzyme removes the stable peroxides from the system, resulting in the reduction of peroxide-induced damage. GPx and GST along with glutathione catalyze the reduction of hydrogen peroxide into non-toxic metabolites (Bruce et al., 1982). The reduced GST activity may be due to the inactivation caused by reactive oxygen species (Andallu and Varadacharyulu, 2003). The recovery of these antioxidant enzymes in the V. volvacea treated group can be attributed to protection mediated to organs of synthesis and by increased GSH production.

SOD and CAT enzymes are important scavengers of superoxide ion and hydrogen peroxide. These enzymes prevent the generation of hydroxyl radical and protect the cellular constituents from oxidative damage. A decrease in SOD activity can result in the decreased removal of superoxide anions, which can be harmful to the myocardium (Sharma et al., 2001). Reduction in the activities of these enzymes in the heart tissues of streptozotocin-treated hyperglycemic rats revealed excessive formation of superoxide and hydrogen peroxide anions. Treatment with V. volvacea either impaired the free radical generation or enhanced the activities of SOD and CAT to scavenge the excessive free radicals.

Vitamins C and E were significantly reduced in the heart of streptozotocin-treated groups indicating hyperglycemia caused damages and reduced bioavailability. Vitamin C, a powerful water soluble reducing agent directly scavenges singlet oxygen, superoxide and hydroxyl radicals (Kitts, 1997). Vitamin E, the major lipophilic anti-oxidant present in cell membranes and lipoproteins protects myocardial membranes and inhibiting the oxidation of lipoproteins (Upston et al., 1999). Oral administration of V. volvacea significantly increased the levels of vitamin C and vitamin E in heart tissues.

In the present study, QRS, QT and ST intervals were prolonged in streptozotocin-treated hyperglycemic rats. Widening of QRS is a sign of abnormal interventricular conduction and prolonged QT interval results in ventricular arrhythmia, an indicator of increased CVD risk (Whitsel et al., 2000). Rats treated with V. volvacea showed only minor alterations of the ECG pattern when compared to control indicating protection by the mushroom.

Mushroom compounds, polysaccharides, β-glucans, lectins, lactones, terpenoids, alkaloids, sterols and phenolics (Chung et al., 2010) are found to have anti-oxidant potential. In vitro studies of V. volvacea also showed anti-oxidant activity (Punitha and Rajasekaran, 2014). Mushroom polysaccharides restore pancreatic cell function to increase insulin input leading to reduction of glucose and improve sensitivity of peripheral cells to insulin (Misra et al., 2009). The bioactive polysaccharide β-glucan is abundant in V. volvacea (Cheung, 1996). The cardioprotection offered by the mushroom V. volvacea could primarily be attributed to its hypoglycemic role thereby reducing the oxidative stress and secondarily by reducing the free radicals.

**Conclusion**

Regulating the blood glucose level and balancing the oxidant-anti-oxidant levels, V. volvacea extract could normalize the cardiac tissue damage in hyperglycemic rats. In addition to its extensive use as delicious food,
V. volvacea can be used as a remedy for the prevention and management of cardiovascular complications during diabetes.

**Ethical Issue**

All the procedures were performed in accordance with Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines and approved by the Institution Animal Ethical Committee (51/IAEC/ SASTRA/RPP).

**References**

Aebi H. Catalase in vitro. Methods Enzymol. 1984; 105: 121–26.

Andallu B, Varadacharyulu NCh. Anti-oxidant role of mulberry (Morus indica L. cv. Amantha) leaves in streptozotocin-diabetic rats. Clin Chim Acta. 2003; 338: 3-10.

Baker H, Frank O, De Angelis B, Feingold S. Plasma tocopherol in man at various times after ingesting free or acetylated tocopherol. Nutr Reports Int. 1980; 21: 531-36.

Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999; 48: 1-9.

Bruce A, Freeman D, James C. Biology of disease free radicals and tissue injury. Lab Invest. 1982; 47: 412-26.

Bulteau AL, Lundberg KC, Humphries KM, Sade HA, Szweda LI. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem. 2001; 276: 30057-63.

Cheung PCK. The hypocholesterolemic effect of extracellular polysaccharide from the submerged fermentation of mushroom. Nutr Res. 1996; 16: 1953-57.

Chung MJ, Chung CK, Jeong Y, Ham SS. Anti-cancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells. Nutr Res Pract. 2010; 4: 177-82.

Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clinica Chimica Acta. 2003; 329: 23-38.

Ellman GL. Tissue sulfhydrl groups. Arch Biochem Biophys. 1959; 82: 77-77.

Ferreira ICFR, Barros L, Abreu RMV. Anti-oxidants in wild mushrooms. Curr Med Chem. 2009; 16: 1543-60.

Habig WH, Pabst MJ, Jakoby WB. Glutathione-S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem. 1974; 249: 7130–39.

Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: An overview. Meth Enzymol. 1990; 186: 1-85.

Hwang HJ, Kim SW, Lim JM, Joo JH, Kim HO, Kim HM, Yun JW. Hypoglycemic effect of crude exopolysaccharides produced by a medicinal mushroom Phellinus baumii in streptozotocin-induced diabetic rats. Life Sci. 2005; 76: 3069-80.

Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys. 1984; 21: 130–32.

Kitts DD. An evaluation of the multiple effects of the anti-oxidant vitamins. Trends Food Sci Techno. 1997; 8: 198-203.

Kondeti VK, Badri KR, Maddirala DR, Thur SK, Fatima SS, Kasetti RB, Rao CA. Effect of Phellinus santisinus bark, on blood glucose, serum lipids, plasma insulin and hepatic carbohydrate metabolic enzymes in streptozotocin induced diabetic rats. Food Chem Toxicol . 2010; 48: 1281-87.

Levine RL, Williams JA, Stadman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994; 233: 346-57.

Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress and anti-oxidants: A review. J Biochem Mol Toxicol. 2003; 17: 24-38.

Misra A, Lalan MS, Singh VK, Govil JN. Role of natural polysaccharides in treatment and control of diabetes. Chemistry and medicinal value. Recent Progr Med Plants. 2009; 25: 347–73.

Nakayama H, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh Y, Nagakawa S. Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rat. Diabetes 1993; 42: 345-50.

Norton GR, Candy G, Woodiwiss AJ. Aminoquinidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93: 1905-12.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem. 1979; 95: 351-38.

Omaye ST, Turnball TD, Sauberlich HE. Selected method for the determination of ascorbic acid in animal fluids. Methods Enzymol. 1979; 62: 3-11.

Okontakte RB, Rao CA. Effect of Pterocarpus santalinus bark, on blood glucose, serum lipids, plasma insulin and hepatic carbohydrate metabolic enzymes in streptozotocin induced diabetic rats. Food Chem Toxicol . 2010; 48: 1281-87.

Punitha SC, Rajasekaran M. Free radical scavenging activity of fruiting body extracts of an edible mushroom, Volvariella volvacea: A macrofungus having nutritional and health potential. Asian J Pharm Tech. 2014; 4: 110-13.
Atherosclerosis 1995; 116: 63-75.

Sharma M, Kishore K, Gupta SK, Joshi S, Arya DS. Cardio-protective potential of Ocimum sanctum in isoproterenol induced myocardial infarction in rats. Mol Cell Biochem. 2001; 225: 75-83.

Upston JM, Terentis AC, Stocker R. Tocopherol-mediated peroxidation of lipoproteins: Implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 1999; 13: 977-94.

Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of QTC in the diagnosis of autonomic failure among patients with diabetes: A meta-analysis. Diabetes Care. 2000; 23: 241-47.

Wasser SP, Weis AL. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: Current perspectives (review). Int J Med Mushr. 1999; 1: 31-62.

Yang B, Kim G, Jeong Y, Jeong H, Mehta P, Song C. Hypoglycemic effects of exo-biopolymers produced by five different medicinal mushrooms in STZ-induced diabetic rats. Mycobiology 2008; 36: 45-49.
Your feedback about this paper

1. Number of times you have read this paper 0

2. Number of times you have seen the video clip 0

3. Quality of paper

4. Your comments